Clinical trials: Dalteparin
Obesity
Venous Thromboprophylaxis in Bariatric Surgery
The main aim of this study is to compare the influence of total body-weight (TBW), lean body-weight (LBW), ideal body-weight (IBW) or Body Mass Index (BMI) on peak anti-Xa levels at steady-state in bariatric surgery (BS) morbidly…
- Trial name
- OBSUD (NCT03218514)
- Testing
- Dalteparin
- Volunteers
- 118 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Healthy
Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin
Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
- Trial name
- NCT00618579
- Testing
- LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ThromboGenics
Morbid Obesity
Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients
Morbid obesity, is known to be associated with a high risk of VTE and, unfortunately, fixed doses of anticoagulant regimens may not provide optimal VTE prophylaxis in these patients especially after surgery.
- Trial name
- NCT05569681
- Testing
- Bemiparin 3500, Bemiparin 5000 IU
- Where
- Iraq
- Volunteers
- 1,248 people, healthy volunteers welcome
- Sponsor
- Hawler Medical University
Venous Thromboembolism
Anti Xa Monitoring Low Molecular Weight Heparin on Prevention of Venous Thromboembolism
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, is a common cardiovascular disease associated with significant morbidity ranging from painful leg swelling, chest pain, shortness of…
- Trial name
- NCT05382481
- Testing
- Peak value anti-Xa, Trough value anti-Xa, Control Group
- Where
- China
- Volunteers
- 858 people
- Sponsor
- Xuanwu Hospital, Beijing
Pregnant Women, Venous Thromboembolic Disease
THROmbinography in Pregnant Woman and in Vitro Action of Low Molecular Weight HEparin
Pregnancy is associated with major changes affecting all satges of hemostasis. Certain procoagulant factors are increased, such as factors VII, VIII, IX, X, XII, fibrinogen and Von Willebrand factor.
- Trial name
- TROPHE (NCT06575309)
- Testing
- Blood test
- Where
- 2 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Clermont-Ferrand
Blood Clot, Thrombosis
Inpatient Monitoring of Unfractionated Heparin
Unfractionated heparin (UFH) is the most widely used intravenous (IV) anticoagulant for treating and preventing thromboembolic disease (e.g., blood clots ). UFH must be closely monitored and adjusted in the hospital.
- Trial name
- NCT06329921
- Testing
- PTT protocol, anti-Xa protocol
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Vanderbilt University Medical Center
Foot Ulcer, Diabetic, Diabetic Angiopathies
Efficacy of a Low-Molecular-Weight Heparin (Bemiparin) in the Treatment of Chronic Foot Ulcers in Diabetic Patients
To assess the efficacy of bemiparin (low molecular weight heparin) for 3 months in the treatment of chronic foot ulcers in diabetic patients.
- Trial name
- NCT00399425
- Testing
- bemiparin (low molecular weight heparin)
- Volunteers
- 84 people
- Sponsor
- Spanish National Health System
Acute Coronary Syndrome, Myocardial Infarction
Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
H-REPLACE trial is a prospective, randomized, open-label, active-controlled, multicenter study in participants with ACS (STEMI or NSTEMI, unstable angina).
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- H-REPLACE (NCT03363035)
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Enoxaparin
- Where
- 24 sites in China
- Volunteers
- 2,055 people
- Sponsor
- Second Xiangya Hospital of Central South University
Non Valvular Atrial Fibrillation
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.
- Trial name
- APIXA-Xa (NCT06862726)
- Testing
- Anti Xa dosage, Dosage of PT-INR
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
This Study Will Provide Data Comparing Safety of LMWH Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment.
Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism
Purpose and rationale: Acute pulmonary embolism (PE) is a common and often fatal disease, with an approximately 30% mortality rate without treatment. Treatment is important to reduce mortality and recurrence in acute PE.
- Trial name
- NCT01956955
- Testing
- enoxaparin ,alteplase, unfractionated heparin
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Ataturk University
Pulmonary Embolism
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006…
- Trial name
- NCT00062803
- Testing
- SR34006, (LMW)heparin, Warfarin VKA
- Where
- 93 sites in United States, Argentina and 18 more
- Sponsor
- Sanofi
Venous Thromboembolism (VTE), Postpartum Care
Informative Video Before LMWH Postpartum - Randomized Controlled Trial
This single-center randomized controlled trial evaluates whether a short informative video can reduce anxiety and pain before the first postpartum administration of low molecular weight heparin (LMWH, Clexane).
- Conditions
- Venous Thromboembolism (VTE), Postpartum Care, Anxiety
- Trial name
- NCT07168005
- Testing
- Informative Video on LMWH, Standard Verbal Explanation
- Where
- Israel
- Volunteers
- 160 people
- Sponsor
- Wolfson Medical Center
Adenocarcinoma of the Colon
Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer
The human body has a natural stress response to surgery, including the formation of blood clots. This response to surgery has been shown to increase metastases (the spread of cancer cells to other organs in the body).
- Trial name
- PERIOP-01 (NCT01455831)
- Testing
- Tinzaparin
- Where
- 16 sites in Belgium, Canada and 1 more
- Volunteers
- 616 people
- Sponsor
- Ottawa Hospital Research Institute
Covid19, Anticoagulant Therapy
Thromboprophylaxis for Patients in ICU With COVID-19
The respiratory distress that goes with COVID-19 infection has been related to a procoagulant state, with thrombosis at both venous and arterial levels, that determines hypoxia and tissue dysfunction at several organs.
- Conditions
- Covid19, Anticoagulant Therapy, Thrombosis
- Trial name
- NCT04623177
- Where
- 31 sites in Spain
- Volunteers
- 822 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Arthritis of the Hip, Transfusion Related Complications
Preoperative Versus Postoperative Start With Thromboprophylaxis in THA (Total Hip Arthroplasty)
The purpose of this study is to determine if there are differences in clinical events, i.e bleeding with associated morbidity, if thromboprophylaxis with LMWH (Low Molecular Weight Heparin) is initiated before or after surgery.
- Conditions
- Arthritis of the Hip, Transfusion Related Complications, Infection, Wound Discharge
- Trial name
- NCT01714297
- Testing
- dalteparin 5000 IU s.c.
- Where
- Norway
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vestre Viken Hospital Trust
Leg Injuries, Winter Sport Resorts
Evaluation of the Prevention of Thromboembolic Disease in Patients With a Lower Limb Trauma, Non Surgical, in Winter Sports Resort
The purpose of this study is to evaluate the impact of thromboembolic diseases and heparin complications in patients with a lower limb trauma supported by physicians of mountain.
- Conditions
- Leg Injuries, Winter Sport Resorts, Outpatients
- Trial name
- M2M-Thrombose (NCT01303523)
- Where
- 28 sites in France
- Volunteers
- 1,627 people
- Sponsor
- Floralis
Drug Interaction
The Effect of ENZAlutamide on the Anti-Xa Levels of Patients Receiving DOACs
This study aims to determine the nature and significance of the theoretical drug interaction between enzalutamide (a drug used to treat prostate cancer) and the direct-acting oral anticoagulant drugs (DOACs).
- Trial name
- ENZA-D (NCT03920566)
- Testing
- Anti-Xa level
- Volunteers
- 15 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Persistent Nonvalvular Atrial Fibrillation
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation
- Trial name
- NCT00171769
- Testing
- Certoparin
- Where
- 2 sites in United States, Germany
- Volunteers
- 200 people
- Sponsor
- Novartis
Pancreatic Cancer, Thromboembolism
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462852
- Testing
- dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis
- Where
- 8 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Thrombosis, Hip Replacement
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.
- Trial name
- NCT00398216
- Testing
- DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
- Where
- 29 sites in United States, Canada and 5 more
- Volunteers
- 903 people
- Sponsor
- Daiichi Sankyo